Summary

Over 60% of patients with major depressive disorder (MDD) who are treated with standard antidepressant therapy (ADT) do not achieve remission. The efficacy and safety of aripiprazole as adjunctive therapy recently have been demonstrated in patients who had an inadequate response to initial ADT [Berman RM et al. J Clin Psychiatry 2007; Marcus RN et al. J Clin Psychopharmacol 2008]. This article discusses posters, presented during the American Psychiatric Association 2008 Annual Meeting, which reported additional analysis of data from the above studies.